Leerink Partnrs increased their FY2024 earnings per share estimates for Werewolf Therapeutics in a report released on Monday, ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Amazon said it is introducing low, upfront pricing for a clinical visit, treatment plan, and free medication delivery for ...

Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical ...

Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on VYGR stock, giving a Buy rating yesterday.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...

Leerink Partners, a leading investment bank specializing in healthcare, announced today the addition of Grant Curry and Jason Truman to its biopharma M&A team. Both have joined Leerink as Senior ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

In the preceding three months, 4 analysts have released ratings for 4D Molecular Therapeutics FDMT, presenting a wide array ...